5 Small Biotech Stocks That Could Get Hotter Than the August Heat презентация

Feeling the heat Much of the U.S. suffers from miserable August temperatures. The stock market, on the other hand, is anything but hot right now. But here are five small biotech stocks that have the potential to bring heat to your portfolio.

Celldex Therapeutics (NASDAQ:CLDX) Celldex currently claims a market cap of $1.6 billion but has yet to post a profit The biotech has 2 drugs in development – brain cancer vaccine Rintega and cancer drug glembatumumab vedotin (glemba)

Why Celldex could heat up Good buying opportunity with recent sell-off due to news about Rintega requiring completion of phase 3 study for approval The stock could easily rebound on positive clinical results for Rintega or glemba

Dynavax Technologies Corp. (NASDAQ:DVAX) Dynavax has been on a roll so far in 2015, with shares soaring over 70% The biotech has four drugs in clinical development, with hepatitis B vaccine HEPLISAV-B getting the most attention

Why Dynavax could heat up Third safety review of HEPLISAV-B phase 3 trial got a thumbs-up in July This is huge because safety concerns derailed FDA approval back in 2013 Shares could rally in anticipation of phase 3 results to be announced in early 2016

Idera Pharmaceuticals (NASDAQ:IDRA) Idera’s market cap stands at $317 million currently The clinical-stage biotech has two drugs in trials – IMO-8400 targeting B-cell lymphomas and IMO-9200 targeting autoimmune diseases

Why Idera could heat up Data from the phase 2 study of IMO-8400 in treating Waldenström's macroglobulinemia is scheduled to be released in 4th quarter Idera will announce target indications for its antisense platform technology later this year

Ligand Pharmaceuticals (NASDAQ:LGND) Ligand shares have soared 76% year-to-date The biotech claims several drugs on the market with its partners – most notably multiple myeloma drug Kyprolis and Promacta, which increases the number of blood platelets

Why Ligand could heat up Solid sales growth for both Kyprolis and Promacta is expected With 120 fully-funded programs and 70 partners, there are lots of opportunities for positive news Partnered cancer drug Evomela expected to launch this year

Portola Pharmaceuticals (NASDAQ:PTLA) Portola is the biggest small biotech on our list with a market cap of $2.6 billion The company has three drugs in clinical trials – anticoagulant Betrixiban, FXa inhibitor antidote Andexanet Alfa, and blood cancer drug Cerdulatinib

Why Portola could heat up Phase 3 study of Betrixiban finishes later this year Andexanet alpha appears to be right on track – with good results from a phase 3 study and a phase 4 confirmatory study rocking along